Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.

@article{Faderl2010FludarabineCM,
  title={Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.},
  author={Stefan J Faderl and William G Wierda and Susan O'brien and Alessandra Ferrajoli and Susan Lerner and Michael J Keating},
  journal={Leukemia research},
  year={2010},
  volume={34 3},
  pages={284-8}
}
Randomized trials demonstrated the superiority of chemoimmunotherapy over chemotherapy in the frontline treatment of CLL. Based on favorable experience with the addition of mitoxantrone (M) to fludarabine (F) plus cyclophosphamide (C), we designed a pilot study testing the combination of FCM plus rituximab (R). Thirty patients with previously untreated, symptomatic CLL, <70 years, and beta-2-microglobulin <twice upper limit of normal were evaluated. Treatment consisted of F 25mg/m(2)/day on… CONTINUE READING